Development and applications of oncolytic Maraba virus vaccines.

IF 6.7
Jonathan G Pol, Matthew J Atherton, Byram W Bridle, Kyle B Stephenson, Fabrice Le Boeuf, Jeff L Hummel, Chantal G Martin, Julia Pomoransky, Caroline J Breitbach, Jean-Simon Diallo, David F Stojdl, John C Bell, Yonghong Wan, Brian D Lichty
{"title":"Development and applications of oncolytic Maraba virus vaccines.","authors":"Jonathan G Pol,&nbsp;Matthew J Atherton,&nbsp;Byram W Bridle,&nbsp;Kyle B Stephenson,&nbsp;Fabrice Le Boeuf,&nbsp;Jeff L Hummel,&nbsp;Chantal G Martin,&nbsp;Julia Pomoransky,&nbsp;Caroline J Breitbach,&nbsp;Jean-Simon Diallo,&nbsp;David F Stojdl,&nbsp;John C Bell,&nbsp;Yonghong Wan,&nbsp;Brian D Lichty","doi":"10.2147/OV.S154494","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunity. To further expand tumor-specific T-cell effector and long-lasting memory compartments, we introduced the MG1 virus in a prime-boost cancer vaccine strategy. To this aim, a replication-incompetent adenoviral [Ad] vector together with the oncolytic MG1 have each been armed with a transgene expressing a same tumor antigen. Immune priming with the Ad vaccine subsequently boosted with the MG1 vaccine mounted tumor-specific responses of remarkable magnitude, which significantly prolonged survival in various murine cancer models. Based on these promising results, we validated the safety profile of the Ad:MG1 oncolytic vaccination strategy in nonhuman primates and initiated clinical investigations in cancer patients. Two clinical trials are currently under way (NCT02285816; NCT02879760). The present review will recapitulate the discoveries that led to the development of MG1 oncolytic vaccines from bench to bedside.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"7 ","pages":"117-128"},"PeriodicalIF":6.7000,"publicationDate":"2018-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S154494","citationCount":"33","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S154494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 33

Abstract

Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunity. To further expand tumor-specific T-cell effector and long-lasting memory compartments, we introduced the MG1 virus in a prime-boost cancer vaccine strategy. To this aim, a replication-incompetent adenoviral [Ad] vector together with the oncolytic MG1 have each been armed with a transgene expressing a same tumor antigen. Immune priming with the Ad vaccine subsequently boosted with the MG1 vaccine mounted tumor-specific responses of remarkable magnitude, which significantly prolonged survival in various murine cancer models. Based on these promising results, we validated the safety profile of the Ad:MG1 oncolytic vaccination strategy in nonhuman primates and initiated clinical investigations in cancer patients. Two clinical trials are currently under way (NCT02285816; NCT02879760). The present review will recapitulate the discoveries that led to the development of MG1 oncolytic vaccines from bench to bedside.

溶瘤马拉巴病毒疫苗的研制与应用。
马拉巴囊泡病毒MG1株的溶瘤活性已在许多临床前癌症模型中证明有效,并且不仅依赖于直接的细胞毒性,而且依赖于先天和适应性抗肿瘤免疫的诱导。为了进一步扩大肿瘤特异性T细胞效应器和持久记忆区,我们在癌症初始疫苗策略中引入了MG1病毒。为此,复制无能的腺病毒[Ad]载体和溶瘤MG1各自用表达相同肿瘤抗原的转基因武装。Ad疫苗的免疫引发随后用MG1疫苗增强,产生了显著程度的肿瘤特异性反应,这显著延长了各种小鼠癌症模型的存活时间。基于这些有希望的结果,我们在非人类灵长类动物中验证了Ad:MG1溶瘤疫苗接种策略的安全性,并启动了癌症患者的临床研究。目前正在进行两项临床试验(NCT02285816;NCT02879760)。本综述将从试验台到床边概述导致MG1溶瘤疫苗开发的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信